BGNE:NSD-BeiGene Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 189.23

Change

0.00 (0.00)%

Market Cap

USD 22.85B

Volume

0.27M

Analyst Target

USD 237.90
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 92.70B
ARGX argenx NV ADR

N/A

USD 35.89B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.38B
MRNA Moderna Inc

N/A

USD 21.00B
UTHR United Therapeutics Corporatio..

N/A

USD 16.70B
RPRX Royalty Pharma Plc

N/A

USD 15.14B
INCY Incyte Corporation

N/A

USD 14.67B
SMMT Summit Therapeutics PLC

N/A

USD 13.75B
PCVX Vaxcyte Inc

N/A

USD 13.28B

ETFs Containing BGNE

MSGR 6.80 % 0.00 %

N/A

N/A
S6EW:SW Ossiam STOXX® Europe 600.. 6.12 % 0.00 %

N/A

USD 0.12B
ELOVD:SW UBS(Lux)Fund Solutions .. 1.98 % 0.00 %

N/A

N/A
ELOW:SW SPDR® EURO STOXX Low Vol.. 1.17 % 0.00 %

N/A

N/A
PHR:CA 0.00 % 0.78 %

N/A

N/A
KURE KraneShares MSCI All Chin.. 0.00 % 0.79 %

N/A

USD 0.04B
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.60 %

N/A

CAD 0.04B
KMED 0.00 % 0.79 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
XRE:CA iShares S&P/TSX Capped RE.. 0.00 % 0.61 %

N/A

CAD 1.48B
FLHK Franklin FTSE Hong Kong E.. 0.00 % 0.09 %

N/A

USD 0.01B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

N/A
LOWE:LSE 0.00 % 0.00 %

N/A

N/A
XMLA:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

N/A

N/A
XMLD:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

N/A

N/A
XS3R:LSE Xtrackers MSCI Europe Con.. 0.00 % 0.00 %

N/A

USD 0.06B
XSNR:LSE Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.03B
XDGM:LSE 0.00 % 0.00 %

N/A

N/A
ELOW:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.02B
EMMV:PA 0.00 % 0.00 %

N/A

N/A
S6EW:PA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

N/A
EUN0:F iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

N/A

N/A
ZPRL:F SPDR® EURO STOXX Low Vol.. 0.00 % 0.00 %

N/A

USD 0.02B
DXSK:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.07B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
EUN0:XETRA iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

USD 0.79B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.16B
OSX9:XETRA 0.00 % 0.00 %

N/A

N/A
UIMY:XETRA 0.00 % 0.00 %

N/A

N/A
ZPRL:XETRA SPDR® EURO STOXX Low Vol.. 0.00 % 0.00 %

N/A

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.00 %

N/A

N/A
LCDE:XETRA BNP Paribas Easy - Low Ca.. 0.00 % 0.00 %

N/A

USD 0.02B
MVEU:SW iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

USD 0.79B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.92% 68% D+ 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.92% 68% D+ 54% F
Trailing 12 Months  
Capital Gain 1.26% 58% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.26% 58% F 40% F
Trailing 5 Years  
Capital Gain -7.19% 72% C 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.19% 72% C 39% F
Average Annual (5 Year Horizon)  
Capital Gain 8.66% 57% F 60% D-
Dividend Return 8.66% 57% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.59% 63% D 37% F
Risk Adjusted Return 16.79% 68% D+ 49% F
Market Capitalization 22.85B 99% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.